Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 82 out of 100. Treatments

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Background Alzheimer's disease is characterized by amyloid-beta (Aβ) plaques and neurofibrillary tangles. The humanized monoclonal antibody solanezumab was designed to increase the clearance from the brain of soluble Aβ, peptides that may lead to toxic effects in the synapses and precede the deposition of fibrillary amyloid. Methods We conducted a double-blind, placebo-controlled, phase 3 trial involving patients with mild dementia due to Alzheimer's disease, defined as a Mini-Mental State Examination (MMSE) score of 20 to 26 (on a scale from 0 to 30, with higher scores indicating better cognition) and with amyloid deposition shown by means of florbetapir positron-emission tomography or Aβ1-42 measurements in cerebrospinal fluid.

What this study adds

Evidence grade: Low

This is a trial of 2,129 participants. This double-blind, placebo-controlled phase 3 trial tested the humanized monoclonal antibody solanezumab, designed to increase clearance of soluble Aβ from the brain, in patients with mild dementia due to Alzheimer's disease. Participants had MMSE scores of 20 to 26 and amyloid deposition shown by florbetapir positron-emission tomography or Aβ1-42 measurements in cerebrospinal fluid.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., et al. (2018). Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease. The New England journal of medicine. https://doi.org/10.1056/nejmoa1705971

Vancouver

Honig LS, Vellas B, Woodward M, Boada M, Bullock R, Borrie M, et al. Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease. The New England journal of medicine. 2018. doi:10.1056/nejmoa1705971. PMID: 29365294.

BibTeX

@article{honig2018-29365294,
  author  = {Honig, L. S. and Vellas, B. and Woodward, M. and Boada, M. and Bullock, R. and Borrie, M. and Hager, K. and Andreasen, N. and others},
  title   = {{Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease}},
  journal = {The New England journal of medicine},
  year    = {2018},
  doi     = {10.1056/nejmoa1705971},
  pmid    = {29365294},
  url     = {https://doi.org/10.1056/nejmoa1705971}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This double-blind, placebo-controlled phase 3 trial tested the humanized monoclonal antibody solanezumab, designed to increase clearance of soluble Aβ from the brain, in patients with mild dementia due to Alzheimer's disease. Participants had MMSE scores of 20 to 26 and amyloid deposition shown by florbetapir positron-emission tomography or Aβ1-42 measurements in cerebrospinal fluid.

Study details

How this study scored 82/100
How this study's score is builtJournal tier 10 of 10; Journal's citation record 4 of 4; Study design 11 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 2 of 5; Sample size 3 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 2 of 2; Times cited 7 of 7; Citations per year 5 of 5; Impact for its field and year 6 of 6; Cited by studies here 4 of 6; Still being cited 4 of 4; Senior author's track record 3 of 4; Institution's track record 2 of 3; Multicenter collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 82 of 100.82 of 100 points earned18 not earned

Published in a top-tier journal, and it is a large phase 3 trial. Scored zero for effect reported because the record does not state it.

ComponentPointsWhy
Journal tier 10 / 10 Tier 1 — top-tier general journal (The New England journal of medicine)
Journal's citation record 4 / 4 New England Journal of Medicine: journal h-index 1,505 (OpenAlex, 2026-10-29)
Study design 11 / 12 A large phase 3 trial (from PubMed type “Clinical Trial, Phase III”)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 2 / 5 2018 — within 10 year(s) of the newest study here
Sample size 3 / 4 2,129 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 2 / 2 Randomized and blinded or placebo-controlled (as stated in the record)
Times cited 7 / 7 Cited 1,047 times (OpenAlex, 2026-10-10)
Citations per year 5 / 5 104.7 citations a year over 10 year(s) since 2018
Impact for its field and year 6 / 6 Cited 78.3× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 4 / 6 Cited by 58 other studies in this library
Still being cited 4 / 4 Cited 260 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Eric Siemers: h-index 56 (OpenAlex, whole career)
Institution's track record 2 / 3 Inserm: institution h-index 1,988 (OpenAlex)
Multicenter collaboration 3 / 3 OpenAlex lists 18 institution(s) in 9 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 29365294)
Free to read 0 / 2 Behind a paywall — scores zero
Total 82 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 13.

Later studies that cite this one

58 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Treatments from nearby years

Also tagged “trial”

783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Treatments

See all studies in Treatments →